Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn&#039;s disease: a multicenter, double-blind, randomized, placebo-controlled trial

Cezard, J-P; Munck, A.; Mouterde, O.; Morali, A.; Lenaerts, C.; Lachaux, A.; Turck, D.; Schmitz, J.; Maurage, C.; Girardet, J-P; Belli, Dominique Charles; Lamireau, T.; Sarles, J.; Chouraqui, J-P; Descos, B.; Dabadi, A.; Meyer, M.; Olives, J-P; Mary, J-Y

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial
Authors		Cezard, J-P Munck, A. Mouterde, O. Morali, A. Lenaerts, C. Lachaux, A. Turck, D. Schmitz, J. Maurage, C. Girardet, J-P Belli, Dominique Charles Lamireau, T. Sarles, J. Chouraqui, J-P Descos, B. Dabadi, A. Meyer, M. Olives, J-P Mary, J-Y show all authors [1 - 19]
Published in		Gastroentérologie clinique et biologique. 2009, vol. 33, no. 1 Pt 1, p. 31-40
Abstract		AIM: This study aimed to test the efficacy of mesalazine in maintaining remission in pediatric Crohn's disease (CD) following successful flare-up treatment. METHODS: In this double-blind, randomized, placebo-controlled trial, 122 patients received either mesalazine 50mg/kg per day (n=60) or placebo (n=62) for one year. Treatment allocation was stratified according to flare-up treatment (nutrition or medication alone). Recruitment was carried out over two periods, as the first period's results showed a trend favoring mesalazine. Relapse was defined as a Harvey-Bradshaw score more than or equal to 5. Time to relapse was analyzed using the Cox model. RESULTS: The one-year relapse rate was 57% (n=29) and 63% (n=35) in the mesalazine and placebo groups, respectively. We demonstrated a twofold lower relapse risk (P<0.02) in patients taking mesalazine in the medication stratum (first recruitment period), and a twofold higher risk in patients taking mesalazine in the nutrition stratum (second recruitment period), compared with the other groups. None of the children's characteristics, which differed across the two recruitment periods, accounted for the between-period variation in mesalazine efficacy. One serious adverse event was reported in each treatment group. CONCLUSION: Overall, mesalazine does not appear to be an effective maintenance treatment in pediatric CD.
Keywords		Anti-Inflammatory Agents, Non-Steroidal/therapeutic use — Child — Crohn Disease/drug therapy — Double-Blind Method — Female — Humans — Male — Mesalamine/*therapeutic use — Recurrence/prevention & control — Treatment Outcome
Identifiers		DOI: 10.1016/j.gcb.2008.07.007 PMID: 19118966
Full text		Article - Limited access to UNIGE Other version: http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=276860&_user=9565874&_pii=S039983200800479X&_check=y&_ori...
Structures		Faculté de médecine / Section de médecine clinique / Département de pédiatrie
Research groups		Gastroentérologie et transplantation (pédiatrie) (181) Plateforme d'oncologie et d'hématologie pédiatrique (907)
Citation (ISO format)		CEZARD, J-P et al. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. In: Gastroentérologie clinique et biologique, 2009, vol. 33, n° 1 Pt 1, p. 31-40. https://archive-ouverte.unige.ch/unige:19732

230 hits

0 download

Contact an author

Update request

Update

Deposited on : 2012-04-23

Export document

Format	:
Citation style	:

Archive ouverte UNIGE

Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial